NUMI Hit $0.53 Up 86% in One Month
Yesterday morning, NUMI hit a high of $0.53 per share for a gain of 85.96% from our breakout point alert exactly one month ago on the morning of September 28th at $0.285 per share.
Yesterday morning, NUMI hit a high of $0.53 per share for a gain of 85.96% from our breakout point alert exactly one month ago on the morning of September 28th at $0.285 per share.
Compass Pathways (CMPS) was featured on CNBC today, causing the stock to gain by $4.19 or 12.25% to close at $38.39 per share. Here is a video of the segment.
NUMI has just made history by harvesting the first legal flush of Psilocybe mushrooms in Canada by a public company under its Health Canada-issued Controlled Drugs and Substances Dealer’s Licence.
Psychstocks is extremely excited to announce its new #1 favorite psilocybin biotechnology stock suggestion: Revive Therapeutics (CSE: RVV). Revive also has a U.S. OTC symbol: RVVTF.
Psychstocks is getting ready to announce its #1 favorite psilocybin biotechnology stock suggestion!
Compass Pathways (CMPS) gained by $3.66 or 10.41% yesterday to close at $38.82 per share for its second biggest up day since its IPO less than one month ago.
On November 3rd, Washington DC will be voting on Initiative 81 to make the enforcement of laws against natural plant medicines among the lowest law enforcement priorities.
Our #1 favorite psychstock NUMI is up 10.17% today to a new 3-month high of $0.325 per share!
Thank you for visiting Psychstocks.com an organization that is dedicated to discovering the future leaders of the emerging psychedelic plant medicine industry. Learn about our organization and founder by reading this article.
Following the release of Citron Research’s bullish report on Compass Pathways (CMPS), the stock gained as much as 28.44% to reach a new record high of $47.29 per share, but only finished the day up by 8.91% to $40.10 per share. We believe Andrew Left made a mistake by releasing his report before the open of trading.
Andrew Left’s Citron Research issued a research report today on Compass Pathways (CMPS) giving it a target price of $100 per share.
On November 3rd, residents of Oregon will vote on Oregon Measure 109, the Psilocybin Mushroom Services Program Initiative of 2020.
NUMI has just surpassed its key breakout point while CMPS is now up by 153.94% from its IPO price in only six trading days with its valuation surpassing $1.5 billion!
NUMI has begun cultivating Psilocybe mushrooms, for the purpose of psilocybin production, at its 7000 square-foot Health Canada licensed facility.
The total gross proceeds from CMPS’s IPO were $146.6 million after sale of additional 1,125,000 ADSs.
CMPS raises $127.5 million at IPO price of $17 per ADS.
Our friends at the Non-Profit MAPS have successfully raised $30 million through the Capstone Campaign to be used to seek FDA approval of MDMA-assisted psychotherapy for PTSD.
We are excited to announce Numinus Wellness (TSXV: NUMI) as our #1 Favorite Pick of 2020